Cefeditorin (Cefditorenum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Cephalosporins

Included in the formulation
  • Spectrate
    pills inwards 
    Meiji Seika Pharma Co., Ltd.     Japan
    • АТХ:

    J.01.D.D.16   Cefeditorin

    Pharmacodynamics:

    Cephalosporin III generation.

    Has bactericidal action due to inhibition of bacterial cell wall synthesis. Violates the synthesis of the biopolymer peptidoglikana - the main component of the cell wall of bacteria. It inhibits the peptidoglycan transpeptidase, inhibits the activity of the endogenous inhibitor, which leads to activation of murein hydrolase, which cleaves peptidoglycan. Effective against fissile bacteria, in the walls of which the synthesis of peptidoglycan occurs.

    It is active against gram-positive microorganisms: Streptococci groups C and G, methicillin-sensitive strains Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes; Gram-negative microorganisms: Haemophilus influenzae, Moraxella catarrhalis, as well as with respect to anaerobic microorganisms: Clostridium perfringens, Peptostreptococcus spp.

    Inactive against gram-positive microorganisms: Enterococcus spp., methicillin-resistant strains Staphylococcus aureus; Gram-negative microorganisms: Acinetobacter baumannii, Pseudomonas aeruginosa; for anaerobic microorganisms: Bacteroides fragilis, Clostridium difficile, and others: Chlamydia spp., Mycoplasma spp., Legionella spp.

    Pharmacokinetics:

    After oral administration, an empty stomach is absorbed up to 20% in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 2.5 hours. The connection with plasma proteins is 88%.

    It is hydrolyzed in the intestine to inactive metabolites.

    Half-life is 1.5 hours. Elimination by the kidneys and with feces.

    Indications:

    It is used for treatment infections caused by microorganisms sensitive to cefditoren: upper (acute tonsillopharyngitis, acute sinusitis) and lower respiratory tract (exacerbation of chronic bronchitis, community-acquired pneumonia); uncomplicated infections of the skin and subcutaneous fat (phlegmon, infected skin wounds, abscess, folliculitis, impetigo and furunculosis).

    ICD-10

    X.J00-J06.J01   Acute Sinusitis

    X.J30-J39.J32.9   Chronic sinusitis, unspecified

    X.J30-J39.J31.2   Chronic pharyngitis

    X.J00-J06.J02   Acute pharyngitis

    X.J00-J06.J03   Acute tonsillitis

    X.J30-J39.J35.0   Chronic tonsillitis

    X.J10-J18.J15   Bacterial pneumonia, not elsewhere classified

    X.J40-J47.J42   Chronic bronchitis, unspecified

    XII.L00-L08.L01   Impetigo

    XII.L00-L08.L02   Abscess of skin, boil and carbuncle

    XII.L00-L08.L03   Phlegmon

    XII.L00-L08.L08.0   Pyoderma

    XIX.T79.T79.3   Post-traumatic wound infection, not elsewhere classified

    Contraindications:

    Individual intolerance of β-lactam antibiotics: penicillins and cephalosporins, children under 12 years.

    Carefully:

    Imbalance of electrolytes or fluid, a history of bronchial asthma, severe liver damage, malabsorption syndrome.

    Pregnancy and lactation:

    Recommendations for FDA - Category B. It is used in pregnancy and lactation.

    Dosing and Administration:

    Inside, after eating, 200 mg every 12 hours. In severe cases of nosocomial pneumonia: 400 mg every 12 hours for 14 days.

    The highest daily dose: 800 mg.

    The highest single dose: 400 mg.

    Side effects:

    Central and peripheral nervous system: headache, dizziness.

    Hemopoietic system: leukopenia, thrombocytopenia, hemolytic anemia, eosinophilia, hypoprothrombinemia.

    Digestive system: nausea, vomiting, diarrhea, cholestatic jaundice, pseudomembranous colitis, increased activity of hepatic transaminases, hepatitis.

    Dermatological reactions: hyperhidrosis, rash, itching, candidiasis.

    Urinary system: interstitial nephritis.

    Allergic reactions.

    Overdose:

    Increased side effects.

    Treatment is symptomatic.

    Interaction:

    Strengthens the effect of indirect coagulants.

    When used simultaneously with aminoglycosides, butadione, polymyxins, the risk of nephrotoxicity increases.

    Salicylates and indomethacin slow the excretion of cefditoren.

    Increase the effect of aminoglycosides, metronidazole, polymyxins, rifampicin, weaken - levomitsetin, tetracyclines.

    Kolestyramin reduces the absorption of cefditoren.

    Special instructions:

    Control of prothrombin time and bleeding time.

    During treatment, a false positive Coombs reaction and a false positive urine reaction to glucose are possible.

    During treatment with cefditoren, alcohol should be avoided - disulfiram-like reactions are possible.

    Instructions
    Up